A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma (NCT06234605)
A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC- 7366 in Combination With Belzutifan (WELIREG™) in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalation, and a combination dose expansion. Approximately 80 patients will be enrolled in this study (up to 20 patients will be enrolled into the HC-7366 monotherapy cohort, up to 30 patients into the combination dose escalation, and up to 30 patients into the combination dose expansion). The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Who can join: Review the eligibility criteria below.
Location: University of Arizona Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- University of Arizona Cancer Center — Tucson, Arizona
- University of California San Diego Moores Cancer Center — La Jolla, California
- Cedars-Sinai Medical Center — Los Angeles, California
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Lone Tree, Colorado
- Yale - New Haven Hospital — New Haven, Connecticut
- HealthPartners Cancer Research Center — Saint Paul, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
- Providence Cancer Institute — Portland, Oregon
- SCRI Oncology Partners — Nashville, Tennessee
- Texas Oncology — Dallas, Texas
- University of Texas Southwestern Medical Center — Dallas, Texas
- University Medical Center & Texas Tech Health Science Center — Lubbock, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Swedish Medical Center — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (651) 675-0300
Email: mgargano@hibercell.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Stanford, California
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — La Jolla, California
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.